2025
Real-World Analysis of Strategies to Prevent Thrombosis and Bleeding in Adults with ALL Treated with Asparaginase
Mort J, Brighton D, Mautner B, Pierce E, Ghamsari F, Allen C, D’souza D, Patel I, Lawson J, Jackson C, Abernathy K, Yelvington B, Miller R, Dholaria B, Wolfe H, Infield J, Locke S, Shallis R, Duong V, Reed D, Walsh K, LeBlanc T, Keng M, Horton B, Chaer F. Real-World Analysis of Strategies to Prevent Thrombosis and Bleeding in Adults with ALL Treated with Asparaginase. Blood Vessels Thrombosis & Hemostasis 2025, 100065. DOI: 10.1016/j.bvth.2025.100065.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaOdds of thrombosisProphylactic anticoagulationPEG-ASPIncreased rate of thrombosisPrognosis of adult patientsAcute lymphoblastic leukemia therapyPediatric-inspired regimensPeripherally inserted central cathetersRandomized prospective studyRate of thrombosisOdds of bleedingAssociated thrombosisPegylated AsparaginaseLymphoblastic leukemiaThrombotic riskRetrospective studyThrombotic eventsAdult patientsReal-world analysisProspective studyCentral cathetersBleedingMultivariate analysisAnticoagulation
2024
Assessment of Endothelial Function in Patients with COVID-19 Using Peripheral Arterial Tonometry
Moulias A, Koros R, Papageorgiou A, Katechis S, Patrinos P, Trigka-Vasilakopoulou A, Papageorgiou A, Papaioannou O, Akinosoglou K, Leventopoulos G, Tsigkas G, Tzouvelekis A, Davlouros P. Assessment of Endothelial Function in Patients with COVID-19 Using Peripheral Arterial Tonometry. Life 2024, 14: 1512. PMID: 39598310, PMCID: PMC11595729, DOI: 10.3390/life14111512.Peer-Reviewed Original ResearchPeripheral arterial tonometryEndothelial dysfunctionEndothelial functionCOVID-19 patientsCardiovascular complicationsArterial tonometryIncidence of thrombotic eventsAssessment of endothelial functionProportion of COVID-19 patientsProportion of patientsEvaluate endothelial functionFollow-up periodSix-month follow-upMonths post-dischargeCOVID-19-negativePrimary endpointSecondary endpointsNo significant differenceThrombotic eventsCardiovascular eventsPost-dischargeFollow-upLnRHIMatched ControlsPatientsComprehensive secondary analysis of thrombotic events in pediatric patients receiving extracorporeal membrane oxygenation: A prospective cohort study
Hughes T, Treffalls R, Koek W, Dalton H, Karam O, Meyer A. Comprehensive secondary analysis of thrombotic events in pediatric patients receiving extracorporeal membrane oxygenation: A prospective cohort study. Perfusion 2024, 40: 1202-1209. PMID: 39352407, PMCID: PMC12202824, DOI: 10.1177/02676591241289358.Peer-Reviewed Original ResearchExtracorporeal membrane oxygenationMultiple thrombotic eventsThrombotic eventsMembrane oxygenationPediatric extracorporeal membrane oxygenationMulti-center prospective studyEvaluate predictive factorsDays of therapyPlatelet transfusion volumeProspective cohort studyTransfusion volumeBinomial regressionPediatric patientsProlonged ECMOPlatelet volumePredictive factorsProspective studyUnivariate analysisAnti-XaCohort studySeverity scoreHigh riskPatientsAntithrombin IIIScoring toolRisk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis
Venkat R, Redd R, Harris A, Aryee M, Marneth A, Kamaz B, Kim C, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G, How J. Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis. Blood Advances 2024, 8: 6043-6054. PMID: 39293089, PMCID: PMC11635702, DOI: 10.1182/bloodadvances.2024013777.Peer-Reviewed Original ResearchConceptsRisk of bleedingClinically relevant nonmajor bleedingEssential thrombocythemiaBleeding riskPlatelet countCumulative incidenceDana-Farber Cancer Institute and Massachusetts General HospitalAssociated with acquired von Willebrand syndromeCumulative incidence of thrombosisCumulative incidence of bleedingIncreased bleeding riskIncidence of bleedingReduced bleeding riskVon Willebrand syndromeIncidence of thrombosisNonmajor bleedingDNMT3A mutationsMassachusetts General HospitalThrombotic eventsDana-FarberDiabetes mellitusBleedingPatientsRisk factorsTreatment decisionsHereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network
DeSancho M, Suvar E, Roberts J, Tarantino M, Schwartz J, Callis J, Recht M. Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network. Journal Of Thrombosis And Haemostasis 2024, 22: 3183-3190. PMID: 39151704, DOI: 10.1016/j.jtha.2024.07.026.Peer-Reviewed Original ResearchConceptsHereditary antithrombin deficiencyLow-molecular-weight heparinVenous thromboembolismOral anticoagulantsAT concentrateAdverse eventsIncreased risk of venous thromboembolismRisk factorsRisk of venous thromboembolismDirect oral anticoagulantsAmerican ThrombosisSeventy-nine patientsDeep vein thrombosisHemostasis NetworkRecurrent thrombosisConcentrate administrationPulmonary embolismAntithrombin deficiencyThrombotic eventsVein thrombosisProspective studyPredominant manifestationArterial thrombosisGlobal RegistryIncreased riskMilvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome
Tantry U, Raghavakurup L, Becker R, Singh S, Bliden K, Gurbel P. Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome. Expert Opinion On Pharmacotherapy 2024, 25: 1271-1280. PMID: 39072402, DOI: 10.1080/14656566.2024.2385062.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeCoronary syndromeElevated risk of bleedingPathological thrombosisTreatment of acute coronary syndromesClinical thrombotic eventsPhysiological hemostasisRisk of bleedingPrevention of thrombosisFXIa inhibitorsBleeding riskReceptor blockersThrombotic eventsAntiplatelet therapyPlatelet antagonistsAntithrombotic efficacyFXIa inhibitionThrombosisExperimental thrombosisPatientsElevated riskLiterature searchAnticoagulationLarge-scale studiesFXIaHematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Chojecki A, Boselli D, Dortilus A, Hamadeh I, Begley S, Chen T, Bose R, Podoltsev N, Zeidan A, Balmaceda N, Yacoub A, Ai J, Knight T, Ragon B, Shah N, Sanikommu S, Symanowski J, Mesa R, Grunwald M. Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice. Annals Of Hematology 2024, 103: 2837-2843. PMID: 38662203, PMCID: PMC11283405, DOI: 10.1007/s00277-024-05735-7.Peer-Reviewed Original ResearchFollow-up durationPolycythemia veraThrombotic riskClinical practiceMedian follow-up durationHematocrit controlHematocrit levelsCohort study of patientsLow thrombotic riskUS Food and Drug AdministrationMonths of treatmentRisk of thrombosisStudy of patientsJanus kinase inhibitorsResponse to hydroxyureaFood and Drug AdministrationRed blood cell productionBlood cell productionCytoreductive treatmentPainful splenomegalyDose adjustmentMyeloproliferative neoplasmsPlatelet countThrombotic eventsArterial thrombosesDevelopmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review
Bikdeli B, Sadeghipour P, Lou J, Bejjani A, Khairani C, Rashedi S, Lookstein R, Lansky A, Vedantham S, Sobieszczyk P, Mena-Hurtado C, Aghayev A, Henke P, Mehdipoor G, Tufano A, Chatterjee S, Middeldorp S, Wasan S, Bashir R, Lang I, Shishehbor M, Gerhard-Herman M, Giri J, Menard M, Parikh S, Mazzolai L, Moores L, Monreal M, Jimenez D, Goldhaber S, Krumholz H, Piazza G. Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review. Seminars In Thrombosis And Hemostasis 2024, 50: 851-865. PMID: 38176425, DOI: 10.1055/s-0043-1777991.Peer-Reviewed Original ResearchVena cava interruptionDeep vein thrombosisInferior vena cavaVena cava filtersVenous thromboembolismPulmonary embolismVena cavaCava filtersProcedural interruptionsRisk of DVTBilateral deep vein thrombosisInfrarenal inferior vena cavaAcute venous thromboembolismLong-term complicationsSystemic adverse effectsSystemic venous circulationHigh-quality evidenceSuperior vena cavaMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsIVC agenesisVein thrombosisYounger patientsThrombotic eventsRight atrium
2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Podoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.Peer-Reviewed Original ResearchConceptsIncidence of thrombosisPolycythemia veraEssential thrombocythemiaStatin useOlder adultsEnd Results-Medicare databasePopulation-based cohort studyArterial thrombotic eventsSurvival of patientsUse of statinsClaims-based studyRisk of thrombosisCardiovascular morbidityCause mortalityTreatment weighting (IPTW) approachCohort studyOlder patientsOverall survivalThrombotic eventsVenous thrombosisPatient populationPrevious registryStatinsTherapeutic strategiesET subgroupEfficacy of Prostacyclin Anticoagulation in Critically Ill Patients Requiring Extracorporeal Support: A Systematic Review and Meta-Analysis
Aldairi N, Al Ali A, Alabdulqader M, Al Jeraisy M, Cyrus J, Karam O. Efficacy of Prostacyclin Anticoagulation in Critically Ill Patients Requiring Extracorporeal Support: A Systematic Review and Meta-Analysis. Cureus 2023, 15: e39967. PMID: 37416033, PMCID: PMC10320736, DOI: 10.7759/cureus.39967.Peer-Reviewed Original ResearchContinuous renal replacement therapyExtracorporeal membrane oxygenationMolecular adsorbent recirculating systemRenal replacement therapyHypotensive eventsCircuit lifespanReplacement therapyAnticoagulation strategiesMeta-analysisThrombotic eventsExtracorporeal supportSystematic reviewAssociated with fewer bleeding eventsControl seriesProportion of bleedingMortality rateCritically Ill ChildrenCritically ill patientsStatistically significant decreaseMultiple electronic databasesRandomized Controlled TrialsRisk of biasBleeding eventsMembrane oxygenationSupport modalitiesPrognostic Utility of Left Atrial Strain to Predict Thrombotic Events and Mortality in Amyloid Cardiomyopathy
Akintoye E, Majid M, Klein A, Hanna M. Prognostic Utility of Left Atrial Strain to Predict Thrombotic Events and Mortality in Amyloid Cardiomyopathy. JACC Cardiovascular Imaging 2023, 16: 1371-1383. PMID: 37940322, DOI: 10.1016/j.jcmg.2023.01.015.Peer-Reviewed Original ResearchConceptsThrombotic eventsAmyloid cardiomyopathyAtrial fibrillationLA contractileLA strainLA contractile strainModest discriminatory abilityPrognostic staging systemRisk stratification toolLeft Atrial StrainHigh thrombotic riskAtrial strainPrognostic utilityStratification toolPrognostic valueC-statisticRespective HRsStaging systemThrombotic riskACM patientsSD decreaseAF casesPredictive valuePatientsDiscriminatory abilityIron homeostasis governs erythroid phenotype in Polycythemia Vera
Bennett C, Jackson V, Pettikiriarachchi A, Hayman T, Schaeper U, Moir-Meyer G, Fielding K, Ataide R, Clucas D, Baldi A, Garnham A, Li-Wai-Suen C, Loughran S, Baxter E, Green A, Alexander W, Bahlo M, Burbury K, Ng A, Pasricha S. Iron homeostasis governs erythroid phenotype in Polycythemia Vera. Blood 2023, 141: 3199-3214. PMID: 36928379, PMCID: PMC10646816, DOI: 10.1182/blood.2022016779.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesIron homeostasisErythroid phenotypePolycythemia veraRegulator of systemic iron homeostasisGenetic dissectionAssociation studiesSystemic iron homeostasisUK Biobank dataHFE variantsErythroid diseaseMouse model of PVExpression of hepcidinBiobank dataLife-threatening thrombotic eventsActivating mutationsHepcidin expressionPathophysiology of PVPhenotypeHomeostasisMyeloproliferative neoplasmsThrombotic eventsHepcidin upregulationTherapeutic strategiesInflammatory cytokinesEmergent external ventricular drain placement in patients with factor Xa inhibitor-associated intracerebral hemorrhage after reversal with andexanet alfa
Ammar A, Elsamadicy A, Ammar M, Reeves B, Koo A, Falcone G, Hwang D, Petersen N, Kim J, Beekman R, Prust M, Magid-Bernstein J, Acosta J, Herbert R, Sheth K, Matouk C, Gilmore E. Emergent external ventricular drain placement in patients with factor Xa inhibitor-associated intracerebral hemorrhage after reversal with andexanet alfa. Clinical Neurology And Neurosurgery 2023, 226: 107621. PMID: 36791588, DOI: 10.1016/j.clineuro.2023.107621.Peer-Reviewed Original ResearchConceptsAndexanet alfaExtra-axial hemorrhageEVD placementThrombotic eventsNew hemorrhagePrimary safety outcomeExternal ventricular drain placementLarge prospective studiesIntensive care unitIntracerebral hemorrhage patientsVentricular drain placementBolus patientsHospital lengthHospital LOSICU LOSTract hemorrhageRankin scoreSecondary outcomesAdult patientsBolus groupPrimary outcomeCare unitIntracerebral hemorrhageLong administration timeHemorrhage patients
2022
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials
Khairani C, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller S, Cortes-Hernandez J, Connors J, Kanthi Y, Krumholz H, Middeldorp S, Falanga A, Cushman M, Goldhaber S, Garcia D, Bikdeli B. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials. Journal Of The American College Of Cardiology 2022, 81: 16-30. PMID: 36328154, PMCID: PMC9812926, DOI: 10.1016/j.jacc.2022.10.008.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsVitamin K antagonistsVenous thromboembolic eventsArterial thrombotic eventsSubsequent venous thromboembolic eventsThrombotic antiphospholipid syndromeMajor bleedingThrombotic eventsK antagonistsOral anticoagulantsAntiphospholipid syndromeUse of DOACsMain efficacy outcomeMain safety outcomeCochrane Central RegisterAdequate allocation concealmentRandom-effects modelRandom sequence generationThromboembolic eventsCentral RegisterEfficacy outcomesArterial thrombosisControlled TrialsRandomized trialsAllocation concealmentAnticoagulation strategies and recurrence of venous thromboembolic events in patients with sickle cell disease: a systematic review and meta-analysis
El-Amin N, Iness A, Cyrus JW, Sisler I, Karam O. Anticoagulation strategies and recurrence of venous thromboembolic events in patients with sickle cell disease: a systematic review and meta-analysis. Annals Of Hematology 2022, 101: 1931-1940. PMID: 35895101, DOI: 10.1007/s00277-022-04901-z.Peer-Reviewed Original ResearchConceptsVenous thromboembolic eventsSickle cell diseaseCell diseaseThromboembolic eventsPulmonary embolismSystematic reviewDevelopment of bleedingOverall bleeding rateVenous thrombotic eventsRisk of mortalityProgression of thrombusAnticoagulant classDifferent anticoagulationAnticoagulation strategiesOverall recurrenceOverall mortalityThrombotic eventsAdverse outcomesPatient populationBleeding rateObservational studyOutcome measuresAppropriate managementPatientsRecurrenceAssociation between oral anticoagulants and COVID-19 related outcomes: a population-based cohort study
Wong AY, Tomlinson L, Brown JP, Elson W, Walker AJ, Schultze A, Morton CE, Evans D, Inglesby P, MacKenna B, Bhaskaran K, Rentsch CT, Powell E, Williamson E, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Cockburn J, McDonald HI, Mathur R, Wing K, Forbes H, Eggo RM, Evans SJ, Smeeth L, Goldacre B, Douglas IJ, . Association between oral anticoagulants and COVID-19 related outcomes: a population-based cohort study. British Journal Of General Practice 2022, 72: bjgp.2021.0689. PMID: 35440465, PMCID: PMC9037187, DOI: 10.3399/bjgp.2021.0689.Peer-Reviewed Original ResearchConceptsCOVID-19 outcomesPopulation-based cohort studySevere COVID-19 outcomesSARS-CoV-2Oral anticoagulantsLower riskVASc scoreCohort studyHazard ratioAtrial fibrillationCOVID-19 related outcomesCOVID-19-related deathsPrescribed oral anticoagulantsPrimary care dataBaseline stroke riskOAC useCurrent useStroke riskHospital admissionThrombotic eventsCox regressionOAC usersReduced infection riskGeneral practiceDeath records
2021
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
Escobar M, Castaman G, Boix S, Callaghan M, de Moerloose P, Ducore J, Hermans C, Journeycake J, Leissinger C, Luck J, Mahlangu J, Miesbach W, Mitha I, Négrier C, Quon D, Recht M, Schved J, Shapiro A, Sidonio R, Srivastava A, Stasyshyn O, Vilchevska K, Wang M, Young G, Alexander W, Al‐Sabbagh A, Bonzo D, Macie C, Wilkinson T, Kessler C. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia 2021, 27: 921-931. PMID: 34636112, PMCID: PMC9292935, DOI: 10.1111/hae.14419.Peer-Reviewed Original ResearchConceptsEptacog betaTreatment of bleedingB patientsBleeding episodesHemophilia ASafety profileHemophilia patientsProspective phase 3 clinical trialsManagement of bleeding episodesPhase 3 clinical trialsTreat bleeding episodesPhase 3 trialControl of bleedingExcellent safety profilePaediatric haemophilia patientsPerioperative haemostasisPreoperative infusionClinical responseRandomized crossover designPerioperative useThrombotic eventsPost-operativelyData monitoring committeeFDA approvalPerioperative careComparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines
Hwang J, Lee S, Lee S, Lee M, Koyanagi A, Jacob L, Tizaoui K, Yon D, Shin J, Smith L. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines. Journal Of Autoimmunity 2021, 122: 102681. PMID: 34139631, PMCID: PMC8204660, DOI: 10.1016/j.jaut.2021.102681.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisChAdOx1 nCoV-19Vaccine-induced thrombotic thrombocytopeniaNCoV-19Vector vaccinesManagement of cerebral venous thrombosisAdenoviral vector vaccinesAPTT levelsClinical presentationThrombotic thrombocytopeniaD-dimerThrombotic eventsVenous thrombosisIntracerebral hemorrhageClinical assessmentAstra ZenecaCOVID-19 vaccineVaccineThrombosisRuxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database
Tremblay D, Ronner L, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Mesa R, Yacoub A, Hoffman R, Moshier E, Zubizarreta N, Mascarenhas J. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leukemia Research 2021, 109: 106629. PMID: 34082375, DOI: 10.1016/j.leukres.2021.106629.Peer-Reviewed Original ResearchConceptsMulti-institutional databaseRuxolitinib discontinuationPolycythemia veraLarge multi-institutional databaseAvailable salvage therapiesDiscontinuation of ruxolitinibTreatment of patientsFurther therapeutic developmentLast followSalvage therapyCytoreductive therapyAdverse eventsPatient characteristicsThrombotic eventsTreatment initiationSimilar patientsDisease characteristicsDismal outcomeFavorable outcomeSalvage strategyPV patientsDiscontinuationInterferon αPatientsRuxolitinibEffect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit
Mazloomzadeh S, Khaleghparast S, Ghadrdoost B, Mousavizadeh M, Baay M, Noohi F, Sharifnia H, Ahmadi A, Tavan S, Malekpour Alamdari N, Fathi M, Soleimanzadeh M, Mostafa M, Davoody N, Zarinsadaf M, Tayyebi S, Farrokhzadeh F, Nezamabadi F, Soomari E, Sadeghipour P, Talasaz A, Rashidi F, Sharif-Kashani B, Beigmohammadi M, Farrokhpour M, Sezavar S, Payandemehr P, Dabbagh A, Moghadam K, Jamalkhani S, Khalili H, Yadollahzadeh M, Riahi T, Rezaeifar P, Tahamtan O, Matin S, Abedini A, Lookzadeh S, Rahmani H, Zoghi E, Mohammadi K, Sadeghipour P, Abri H, Tabrizi S, Mousavian S, Shahmirzaei S, Bakhshandeh H, Amin A, Rafiee F, Baghizadeh E, Mohebbi B, Parhizgar S, Aliannejad R, Eslami V, Kashefizadeh A, Kakavand H, Hosseini S, Shafaghi S, Ghazi S, Najafi A, Jimenez D, Gupta A, Madhavan M, Sethi S, Parikh S, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Piazza G, Kirtane A, Van Tassell B, Dobesh P, Stone G, Lip G, Krumholz H, Goldhaber S, Bikdeli B. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. JAMA 2021, 325: 1620-1630. PMID: 33734299, PMCID: PMC7974835, DOI: 10.1001/jama.2021.4152.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsCOVID-19Drug Administration ScheduleEnoxaparinExtracorporeal Membrane OxygenationFemaleHemorrhageHospitalizationHumansIntensive Care UnitsIranLength of StayMaleMiddle AgedOdds RatioOutcome Assessment, Health CareOxygen Inhalation TherapyPulmonary EmbolismThrombocytopeniaThrombosisTreatment OutcomeVenous ThrombosisConceptsStandard-dose prophylactic anticoagulationIntensive care unitIntermediate-dose groupProphylactic anticoagulationPrimary efficacy outcomeExtracorporeal membrane oxygenationIntermediate doseMajor bleedingProphylaxis groupEfficacy outcomesMembrane oxygenationPrimary outcomeThrombotic eventsArterial thrombosisCare unitSevere thrombocytopeniaCOVID-19Bleeding Academic Research ConsortiumExtracorporeal membrane oxygenation treatmentPrespecified safety outcomesRoutine empirical useStandard prophylactic anticoagulationAcademic Research ConsortiumMembrane oxygenation treatmentAntithrombotic prophylaxis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply